-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Sepsis is a serious global health problem and one of the leading causes of death and disability.
Obtaining a simple, community-based prevention strategy can greatly reduce the burden of sepsis.
Therefore, recently Eisen DP et al.
published a study online in Lancet Respir Med (IF=25.
094) to observe whether low-dose aspirin can reduce the rate of sepsis-related death or hospitalization in the elderly.
Research Overview The ASPREE study conducted a randomized controlled primary prevention trial comparing low-dose aspirin [100 mg/d] vs placebo in Australia and the United States to elderly people living in the community.
ANTIEPSIS is a sub-study of the ASPREE study and included Australian cohort crowd.
The study included participants over 70 years of age without major diseases.
Participants were divided into 1:1 groups through the central portal and stratified according to general practice and age.
Participants, researchers and staff are unaware of the intervention methods.
The clinical expert investigation team evaluates potential sepsis events to determine whether the primary endpoint of sepsis-related death is met.
Univariate survival analysis method, log-rank test and Cox proportional hazard regression were used for analysis.
Research results From March 10, 2010 to December 24, 2014, among 20,288 patients who underwent eligibility assessment, 16,703 elderly participants over the age of 70 were included in the trial, with a median follow-up of 4.
6 years (IQR 3.
6–5.
6).
8322 participants (49.
8%) received aspirin treatment, and 8381 participants (50.
2%) received placebo treatment.
203 deaths are considered to be related to sepsis.
Univariate analysis showed that sepsis-related mortality was similar in the two study groups (hazard ratio of aspirin vs placebo was 1.
08, 95% CI 0.
82–1.
43; p=0.
57).
Research conclusions The investigators concluded that daily low-dose aspirin in the elderly in the community did not reduce sepsis-related deaths.
The results of this study do not support the use of aspirin as a primary prevention strategy to reduce the burden of sepsis in this population.
Yimaitong compiled from: Eisen DP, et al.
Effect of aspirin on deaths associated with sepsis in healthy older people (ANTISEPSIS): a randomised, double-blind, placebo-controlled primary prevention trial.
Lancet Respir Med.
2020 Sep 17: S2213-2600(20)30411-2.
Obtaining a simple, community-based prevention strategy can greatly reduce the burden of sepsis.
Therefore, recently Eisen DP et al.
published a study online in Lancet Respir Med (IF=25.
094) to observe whether low-dose aspirin can reduce the rate of sepsis-related death or hospitalization in the elderly.
Research Overview The ASPREE study conducted a randomized controlled primary prevention trial comparing low-dose aspirin [100 mg/d] vs placebo in Australia and the United States to elderly people living in the community.
ANTIEPSIS is a sub-study of the ASPREE study and included Australian cohort crowd.
The study included participants over 70 years of age without major diseases.
Participants were divided into 1:1 groups through the central portal and stratified according to general practice and age.
Participants, researchers and staff are unaware of the intervention methods.
The clinical expert investigation team evaluates potential sepsis events to determine whether the primary endpoint of sepsis-related death is met.
Univariate survival analysis method, log-rank test and Cox proportional hazard regression were used for analysis.
Research results From March 10, 2010 to December 24, 2014, among 20,288 patients who underwent eligibility assessment, 16,703 elderly participants over the age of 70 were included in the trial, with a median follow-up of 4.
6 years (IQR 3.
6–5.
6).
8322 participants (49.
8%) received aspirin treatment, and 8381 participants (50.
2%) received placebo treatment.
203 deaths are considered to be related to sepsis.
Univariate analysis showed that sepsis-related mortality was similar in the two study groups (hazard ratio of aspirin vs placebo was 1.
08, 95% CI 0.
82–1.
43; p=0.
57).
Research conclusions The investigators concluded that daily low-dose aspirin in the elderly in the community did not reduce sepsis-related deaths.
The results of this study do not support the use of aspirin as a primary prevention strategy to reduce the burden of sepsis in this population.
Yimaitong compiled from: Eisen DP, et al.
Effect of aspirin on deaths associated with sepsis in healthy older people (ANTISEPSIS): a randomised, double-blind, placebo-controlled primary prevention trial.
Lancet Respir Med.
2020 Sep 17: S2213-2600(20)30411-2.
